Dynavax Technologies Corporation [NASDAQ: DVAX] closed the trading session at $8.23 on 03/05/21. The day’s price range saw the stock hit a low of $7.30, while the highest price level was $8.60. The company report on March 2, 2021 that Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference.
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference being held March 9-10, 2021.
The on demand presentation will be available, beginning Tuesday, March 9, 2021 at 7:00 a.m. E.T. and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.
The stocks have a year to date performance of 84.83 percent and weekly performance of -6.00 percent. The stock has been moved at 45.32 percent over the last six months. The stock has performed -12.59 percent around the most recent 30 days and changed 56.67 percent over the most recent 3-months.
If compared to the average trading volume of 6.13M shares, DVAX reached to a volume of 5194772 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Dynavax Technologies Corporation [DVAX]:
H.C. Wainwright have made an estimate for Dynavax Technologies Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 07, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $14. The new note on the price target was released on August 03, 2020, representing the official price target for Dynavax Technologies Corporation stock. Previously, the target price had yet another raise to $14, while Evercore ISI analysts kept a Outperform rating on DVAX stock.
The Average True Range (ATR) for Dynavax Technologies Corporation is set at 1.07, with the Price to Sales ratio for DVAX stock in the period of the last 12 months amounting to 20.59. The Price to Book ratio for the last quarter was 15.52, with the Price to Cash per share for the same quarter was set at 1.42.
DVAX stock trade performance evaluation
Dynavax Technologies Corporation [DVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.00. With this latest performance, DVAX shares dropped by -12.59% in over the last four-week period, additionally plugging by 45.32% over the last 6 months – not to mention a rise of 95.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DVAX stock in for the last two-week period is set at 47.42, with the RSI for the last a single of trading hit 40.73, and the three-weeks RSI is set at 51.19 for Dynavax Technologies Corporation [DVAX]. The present Moving Average for the last 50 days of trading for this stock 7.23, while it was recorded at 8.55 for the last single week of trading, and 6.31 for the last 200 days.
Dynavax Technologies Corporation [DVAX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Dynavax Technologies Corporation [DVAX] shares currently have an operating margin of -161.59 and a Gross Margin at +62.78. Dynavax Technologies Corporation’s Net Margin is presently recorded at -161.63.
Return on Total Capital for DVAX is now -29.83, given the latest momentum, and Return on Invested Capital for the company is -30.22. Return on Equity for this stock declined to -224.65, with Return on Assets sitting at -23.80. When it comes to the capital structure of this company, Dynavax Technologies Corporation [DVAX] has a Total Debt to Total Equity ratio set at 371.16. Additionally, DVAX Total Debt to Total Capital is recorded at 78.78, with Total Debt to Total Assets ending up at 61.67. Long-Term Debt to Equity for the company is recorded at 365.63, with the Long-Term Debt to Total Capital now at 77.60.
Reflecting on the efficiency of the workforce at the company, Dynavax Technologies Corporation [DVAX] managed to generate an average of -$307,102 per employee. Receivables Turnover for the company is 2.95 with a Total Asset Turnover recorded at a value of 0.15.Dynavax Technologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.70.
Earnings per share (EPS) analysis for Dynavax Technologies Corporation [DVAX] stock
With the latest financial reports released by the company, Dynavax Technologies Corporation posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 51.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DVAX.
Dynavax Technologies Corporation [DVAX]: Insider Ownership positions
There are presently around $692 million, or 74.80% of DVAX stock, in the hands of institutional investors. The top three institutional holders of DVAX stocks are: FEDERATED HERMES, INC. with ownership of 11,946,800, which is approximately 9.135% of the company’s market cap and around 0.20% of the total institutional ownership; BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding 10,895,773 shares of the stock with an approximate value of $89.62 million in DVAX stocks shares; and STATE STREET CORP, currently with $89.55 million in DVAX stock with ownership of nearly -6.169% of the company’s market capitalization.
Positions in Dynavax Technologies Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 65 institutional holders increased their position in Dynavax Technologies Corporation [NASDAQ:DVAX] by around 7,407,086 shares. Additionally, 77 investors decreased positions by around 11,407,926 shares, while 34 investors held positions by with 65,306,621 shares. The mentioned changes placed institutional holdings at 84,121,633 shares, according to the latest SEC report filing. DVAX stock had 12 new institutional investments in for a total of 156,900 shares, while 33 institutional investors sold positions of 2,526,885 shares during the same period.